The 5 lipoxygenase system in the vasculature: Emerging role in health and disease

被引:52
作者
Osher, Etty
Weisinger, Gary
Limor, Rona
Tordjman, Karen
Stern, Naftali [1 ]
机构
[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Inst Endocrinol Metab & Hypertens, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Inst Endocrinol Metab & Hypertens, IL-64239 Tel Aviv, Israel
关键词
5; lipoxygenase; leukotrienes; cysteinyl-leukotrienes; vascular cells;
D O I
10.1016/j.mce.2006.03.038
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Activation of the 5 lipoygenase (5LO) system within the vascular bed requires the presence of several cell types with distinct transcellular cross-talk mechanisms, resulting in the generation of 5LO produced metabolites and increased expression of receptors for these metabolites in vascular cells. The key products in this system, the leukotriens LTB4, LTC4 and LTD4, are potent mediators of vascular inflammation initiated by white blood cells and sustained or propagated thereafter through amplified metabolite generation and direct effects in endothelial and vascular smooth muscle cells. Leukotrienes act to enhance cell permeability and increase oxidative stress, vascular smooth muscle cell migration and arterial tone. 5LO activation is highly regulated, and is apparently both model/species-specific and region-specific. 5LO activation is also linked to plaque progression, plaque stability, activation of matrix metalloproteinases, propensity to coronary and cerebrovascular events and the evolution of aortic aneurysms. Generic variants in the 5LO activating protein are strongly linked to increased cardiovascular risk and may serve as useful markers for future therapy targeting down regulation of 5LO expression and activity as a means to combat cardiovascular disease. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 45 条
[1]   Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice [J].
Aiello, RJ ;
Bourassa, PA ;
Lindsey, S ;
Weng, WF ;
Freeman, A ;
Showell, HJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (03) :443-449
[2]   Differential leukotriene constrictor responses in human atherosclerotic coronary arteries [J].
Allen, S ;
Dashwood, M ;
Morrison, K ;
Yacoub, M .
CIRCULATION, 1998, 97 (24) :2406-2413
[3]   PREFERENTIAL VASOCONSTRICTION TO CYSTEINYL LEUKOTRIENES IN THE HUMAN SAPHENOUS-VEIN COMPARED WITH THE INTERNAL MAMMARY ARTERY - IMPLICATIONS FOR GRAFT PERFORMANCE [J].
ALLEN, SP ;
CHESTER, AH ;
DASHWOOD, MR ;
TADJKARIMI, S ;
PIPER, PJ ;
YACOUB, MH .
CIRCULATION, 1994, 90 (01) :515-524
[4]  
BERKOWITZ BA, 1984, J PHARMACOL EXP THER, V229, P105
[5]   Nitric oxide modulation of transcellular biosynthesis of cys-leukotrienes in rabbit leukocyte-perfused heart [J].
Buccellati, C ;
Rossoni, G ;
Bonazzi, A ;
Berti, F ;
Maclouf, J ;
Folco, G ;
Sala, A .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (06) :1128-1134
[6]  
Byrum RS, 1999, J IMMUNOL, V163, P6810
[7]   Association between 5-lipoxygenase expression and plaque instability in humans [J].
Cipollone, F ;
Mezzetti, A ;
Fazia, ML ;
Cuccurullo, C ;
Iezzi, A ;
Ucchino, S ;
Spigonardo, F ;
Bucci, M ;
Cuccurullo, F ;
Prescott, SM ;
Stafforini, DM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (08) :1665-1670
[8]   Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis [J].
Dwyer, JH ;
Allayee, H ;
Dwyer, KM ;
Fan, J ;
Wu, HY ;
Mar, R ;
Lusis, AJ ;
Mehrabian, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (01) :29-37
[9]   Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin [J].
Fiorucci, S ;
Distrutti, E ;
Mencarelli, A ;
Morelli, A ;
Laufer, SA ;
Cirino, G ;
Wallace, JL .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (07) :1351-1359
[10]   Mechanisms underlying endothelium-dependent, nitric oxide- and prostanoid-independent relaxation in monkey and dog coronary arteries [J].
Fujioka, H ;
Ayajiki, K ;
Shinozaki, K ;
Toda, N ;
Okamura, T .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 366 (05) :488-495